| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma |
|
Medicine details |
|
| Medicine name | pazopanib (Votrient®) |
| Formulation | film-coated tablet |
| Reference number | 239 |
| Indication | First line treatment of advanced renal cell carcinoma and for patients who have received prior cytokine therapy for advanced disease |
| Company | GlaxoSmithKline |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/03/2010 |
| NICE guidance | TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma |